Roche Holding AG

SWX:ROG Stock Report

Market Cap: CHF 257.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Roche Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Thomas Schinecker

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3yrs
CEO ownership0.0004%
Management average tenure6yrs
Board average tenure6yrs

Recent management updates

Recent updates

Narrative Update • Mar 21

ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential

Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
Narrative Update • Mar 07

ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside

The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.
Narrative Update • Feb 21

ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead

Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
Narrative Update • Feb 07

ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating

Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.
Analysis Article • Feb 03

Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
New Narrative • Feb 01

Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond

About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.
Narrative Update • Jan 23

ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating

Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.
Narrative Update • Jan 09

ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution

Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.
Narrative Update • Dec 17

ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead

Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.
Narrative Update • Dec 03

ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead

Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.
Narrative Update • Nov 19

ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead

Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.
Analysis Article • Aug 20

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...
Analysis Article • Jun 24

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Narrative • Feb 04

Roche Holding will see a 4.2576% revenue growth shaking the market

### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
User avatar
New Narrative • Feb 02

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.

CEO Compensation Analysis

How has Thomas Schinecker's remuneration changed compared to Roche Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

CHF 13b

Sep 30 2025n/an/a

CHF 11b

Jun 30 2025n/an/a

CHF 9b

Mar 31 2025n/an/a

CHF 9b

Dec 31 2024n/an/a

CHF 8b

Sep 30 2024n/an/a

CHF 9b

Jun 30 2024n/an/a

CHF 11b

Mar 31 2024n/an/a

CHF 11b

Dec 31 2023n/an/a

CHF 11b

Sep 30 2023n/an/a

CHF 11b

Jun 30 2023n/an/a

CHF 11b

Mar 31 2023n/an/a

CHF 12b

Dec 31 2022CHF 5mCHF 1m

CHF 12b

Sep 30 2022n/an/a

CHF 14b

Jun 30 2022n/an/a

CHF 15b

Mar 31 2022n/an/a

CHF 14b

Dec 31 2021CHF 4mCHF 1m

CHF 14b

Sep 30 2021n/an/a

CHF 14b

Jun 30 2021n/an/a

CHF 14b

Mar 31 2021n/an/a

CHF 14b

Dec 31 2020CHF 4mCHF 879k

CHF 14b

Sep 30 2020n/an/a

CHF 14b

Jun 30 2020n/an/a

CHF 13b

Mar 31 2020n/an/a

CHF 13b

Dec 31 2019CHF 2mCHF 609k

CHF 13b

Compensation vs Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the Swiss market.

Compensation vs Earnings: Thomas's compensation has increased by more than 20% in the past year.

CEO

Thomas Schinecker (50 yo)

3yrs
Tenure
CHF 5,335,592
Compensation

Dr. Thomas Schinecker is Chairman of the Board of Roche Holdings, Inc. from March 14, 2023. Dr. Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the B...

Leadership Team

NamePositionTenureCompensationOwnership
Severin Schwan
Executive Chairman13yrsCHF 11.48m0.045%
CHF 115.3m
Thomas Schinecker
Group Chief Executive Officer3yrsCHF 5.34m0.00045%
CHF 1.2m
Alan Hippe
Chief Financial Officer14.9yrsCHF 6.05m0.0066%
CHF 17.1m
Bruno Eschli
Head of Investor Relationsno datano datano data
Claudia Bockstiegel
General Counsel5.9yrsno datano data
Pascale Schmidt
Chief Compliance Officer6.2yrsno datano data
Nina Schwab-Hautzinger
Head of Group Communicationsless than a yearno datano data
Maria Cristina Wilbur
Chief People Officer10yrsCHF 4.25m0.0022%
CHF 5.6m
Nicolas Dunant
Head of Group Media Relationsno datano datano data
Boris L. Zaitra
Head of Corporate Business Developmentno datano datano data
Cristin Hubbard
Senior Vice President of Immunologyno datano datano data
Sascha Fauser
Global Head of Ophthalmology Roche pREDno datano datano data
6.0yrs
Average Tenure
55.5yo
Average Age

Experienced Management: ROG's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Severin Schwan
Executive Chairman13yrsCHF 11.48m0.045%
CHF 115.3m
Ulf Schneider
Director3yrsno data0.00063%
CHF 1.6m
Andre Hoffmann
Independent Vice Chairman30.2yrsCHF 400.00k3.54%
CHF 9.1b
Patrick Frost
Independent Non Executive Director6yrsCHF 360.00k0.00050%
CHF 1.3m
Richard Lifton
Non-Executive Independent Director11.2yrsCHF 346.71k0%
CHF 0
Anita Hauser
Non-Executive Independent Director9yrsCHF 336.16k0.00059%
CHF 1.5m
Lubomira Rochet
Directorno datano datano data
Jorg Duschmale
Non-Executive Independent Director6yrsCHF 394.67kno data
Akiko Iwasaki
Director3yrsno datano data
Jemilah Mahmood
Independent Non-Executive Director4yrsCHF 272.50kno data
6.0yrs
Average Tenure
57.5yo
Average Age

Experienced Board: ROG's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/16 15:49
End of Day Share Price 2026/03/16 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 43 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research
Mark PurcellBarclays